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Background: Cytochrome c is an essential mediator of apoptosis when it is released from the mitochondria to the
cytoplasm. This process normally takes place in response to DNA damage, but in many cancer cells (i.e., cancer stem cells)
it is disabled due to various mechanisms. However, it has been demonstrated that the targeted delivery of Cytochrome c
directly to the cytoplasm of cancer cells selective initiates apoptosis in many cancer cells. In this work we designed a
novel nano-sized smart Cytochrome c drug delivery system to induce apoptosis in cancer cells upon delivery.
Results: Cytochrome c was precipitated with a solvent-displacement method to obtain protein nanoparticles. The size
of the Cytochrome c nanoparticles obtained was 100-300 nm in diameter depending on the conditions used, indicating
good potential to passively target tumors by the Enhanced Permeability and Retention effect. The surface of Cytochrome
c nanoparticles was decorated with poly (lactic-co-glycolic) acid-SH via the linker succinimidyl 3-(2-pyridyldithio)
propionate to prevent premature dissolution during delivery. The linker connecting the polymer to the protein
nanoparticle contained a disulfide bond thus allowing polymer shedding and subsequent Cytochrome c release under
intracellular reducing conditions. A cell-free caspase-3 assay revealed more than 80% of relative caspase activation by
Cytochrome c after nanoprecipitation and polymer modification when compared to native Cytochrome c. Incubation
of HeLa cells with the Cytochrome c based-nanoparticles showed significant reduction in cell viability after 6 hours
while native Cytochrome c showed none. Confocal microscopy confirmed the induction of apoptosis in HeLa
cells when they were stained with 4’,6-diamidino-2-phenylindole and propidium iodide after incubation with
the Cytochrome c-based nanoparticles.
Conclusions: Our results demonstrate that the coating with a hydrophobic polymer stabilizes Cytochrome c
nanoparticles allowing for their delivery to the cytoplasm of target cells. After smart release of Cytochrome c into
the cytoplasm, it induced programmed cell death.
Keywords: Drug delivery, Protein nanoparticles, PLGA, Passive targeting, Triggered releaseBackground
Cytotoxic drugs (such as, cis- and carboplatin, doxorubicin,
5-fluorouracil, gemcitabine, paclitaxel, out of a list of over
50) are still commonly used in chemotherapy to stop
cancer cells from multiplying and dispersing. These drugs
affect all growing cells, but since most normal cells do not
divide as often as cancer cells they are proportionately less* Correspondence: kai.griebenow@gmail.com
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article, unless otherwise stated.affected. Unfortunately, the lack of tumor specificity of
these cytotoxins produces unwanted and often severe and
dangerous side effects. One approach to overcome this
is the development of nano-sized drug delivery systems
(DDS), which have been shown to increase the drug
accumulation in tumors via passive targeting, i.e., through
the enhanced permeation and retention (EPR) effect [1-3].
Two types of nano-sized DDS, liposomes and albumin
nanoparticles (NPs), i.e. Doxil® and Abraxane®, respectively,
have caused notable improvements in the therapeutic
efficacy of anticancer agents [4]. However, also theseentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Morales-Cruz et al. Journal of Nanobiotechnology 2014, 12:33 Page 2 of 11
http://www.jnanobiotechnology.com/content/12/1/33therapeutics still display significant side effects and only
prolong life marginally. The lack of success in improving
overall survival in many solid tumors and the still signifi-
cant side effects of even the second generation drugs make
it imperative to further develop and refine such DDS.
All currently US FDA approved chemotherapeutic DDS
and most that are in current clinical trials or in vivo
studies still employ traditional cytotoxic drugs as their
therapeutic agents. Many of these chemotherapeutic agents
(e.g., alkylating agents and antimetabolites) produce DNA
damage which leads to p53-dependent apoptosis [5].
Indeed, the loss of the p53 tumor suppressor pathway
contributes to the development of most human cancers
[6]. Thus, inactivation of the apoptotic response provides
an attractive explanation for the poor responsiveness of
p53 mutant tumors to many traditional anticancer agents.
Such limitations have spurred efforts to identify new
and more effective chemotherapeutic agents that act
independently of the p53 pathway. The high selectivity
and low toxicity of many proteins make them attractive
substitutes of cytotoxic drug. For example, Cytochrome
c (Cyt c) is an important mediator of apoptosis when it
is released from the mitochondria to the cytoplasm
[7,8]. This process normally takes place in response to
DNA damage, but in many cancer cells it is inhibited (most
likely due to inactivation of the upstream components of
the signaling pathway(s) that activates the Cyt c release,
such as the p53 pathway). The targeted delivery of Cyt c
directly to the cytoplasm could selectively initiate apop-
tosis in most cancer cell by circumventing inactivation of
apoptosis due to damage to upstream events.
However, protein drugs also do have significant draw-
backs, primarily related to their limited physical and
chemical stability during storage and after administration
[9-11]. Also, most proteins including Cyt c cannot cross
lipid bilayer membranes [12]. This makes it necessary to
develop methods allowing for the intracellular delivery
of sufficient amounts of Cyt c to induce apoptosis in the
target cells. The development of nanosized carriers for
protein therapeutics allows maintaining protein stability
and controlling release properties but having a sufficiently
high protein loading remains challenging [11,13]. Recently
our research group has been developing strategies for
the intracellular delivery of Cyt c using nanosized DDS
[14,15]. We demonstrated that Cyt c delivered from a
smart nanosized system could potentially be an effective
chemotherapeutic agent to treat cancer, but also recognized
that the delivery system used needed improvement to
achieve a better efficiency. Specifically, we demonstrated
that mesoporous silica nanoparticles (MSN) could be
utilized as efficient carrier for the delivery of apoptosis-
inducing Cyt c [15]. However, Cyt c-MSN conjugates
were not able to induce cell death in HeLa cells during
the first 48 h. They showed 45% cell viability after 72 hat a Cyt c concentration of 37.5 μg/ml. It was not possible
to increment the Cyt c concentration since that resulted
in a toxic concentration of MSN (>100 μg/ml) and the
particles were already loaded to the maximum with the
protein. This demonstrates fundamental limits of such
drug-loaded systems in practical applications. Ideally, to
avoid such limitations, the drug should itself form the
DDS. Consequently, we evolved a delivery system in which
the core consisted of Cyt c NPs and thus the drug itself.
Production of Cyt c NPs by a solvent displacement
method is a straight-forward process (i.e., by solvent-
induced nanoprecipitation) [16]. However, such NPs would
simply dissolve when injected into the blood stream and
thus need to be stabilized for application, e.g., by applying
high temperature and/or chemical cross-linkers [17].
NPs, which were stabilized via a chemical cross-linker
agent with thiol-cleavability, have been successfully used
for triggered drug release mediated by the reducing
environment inside the cell [18]. In this work we tested a
new method for stabilizing Cyt c NPs by covalently coating
them with the hydrophobic polymer poly (lactic-co-gly-
colic) acid (PLGA). PLGA, a biocompatible, biodegradable,
and non-toxic polymer, has been intensely studied in the
field of DDS and has received FDA approval for various
applications including drug delivery [19,20]. Our idea was to
coat the Cyt c NPs with PLGA using a hetero-bifunctional
linker, such as succinimidyl 3-(2-pyridyldithio) propionate
(SPDP), that includes a disulfide bond to be able to shed
the polymer shell in the reducing environment of the
cell (Figure 1A). Afterwards the Cyt c nanoparticle should
dissolve in the cell thus inducing apoptosis (Figure 1B). In
this work we demonstrate the potential of the designed
anti-tumor Cyt c nanoparticle in cancer treatment.
Results and discussion
Nanoprecipitation of Cyt c
Cyt c, an apoptosis-initiating protein, could potentially
be used to target and specifically destroy cancer cells if
delivered to their cytoplasm. Protein-based nanomaterials
have been studied as carriers of anti-cancer drugs because
of their biodegradability, low toxicity, and multiple modifi-
cation capacity [21]. It would be ideal to use the protein as
both, nanosized delivery device and drug, simultaneously.
To test this concept, in this study we generated and tested
Cyt c-based NPs to kill cancer cells by inducing the
apoptosis.
Cyt c nanoparticles were obtained by a solvent displace-
ment method shown to induce a reversible nanoprecipita-
tion of proteins without compromising their frequently
fragile structure and function [14]. In a previous study we
found that acetonitrile was a useful organic solvent for
obtaining Cyt c nanoprecipitates when it was added in at
least 4-fold excess to the aqueous protein solution [14].
In this work we optimized this procedure for obtaining
Figure 1 Schematic representation of the synthesis and application of Cyt c-based NPs. A) Protein nanoprecipitation followed by the
nanoparticles surface modification with PLGA. B) Intracellular stimulus-responsive Cyt c release.
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centration on Cyt c precipitation and stability. While no
buffer-insoluble aggregates were formed regardless of
the protein concentration (data not shown), the precipi-
tation yield decreased at higher protein concentrations
(Figure 2). In agreement with our previous work for other
proteins [14], we also found that at increasing protein
concentration under otherwise constant conditions the
particle size increased (Figure 2). We selected a Cyt c
concentration of 5 mg/ml for further experiments since
it had the highest precipitation efficiency (100%) and
smallest particle diameter (around 150 nm). Note that a
particle diameter of less than 400 nm should result in
particles with good passive delivery properties [2,22,23].
The capability of Cyt c to still interact with Apoptotic
Protease Activating Factor 1 (Apaf-1) and induce apoptosis
after nanoprecipitation was verified next. Since Cyt c is a
cell membrane impermeable protein the experiment was
conducted in a cell-free system. The addition of Cyt c to
fresh cytosol produces caspase activation [15]. Thus, the
integrity of the soluble protein after the nanoprecipitation
procedure was compared with native Cyt c and was foundto be around 90%. We tested the use of the excipient
methyl-β-cyclodextrin (mβCD) to further increase the
Cyt c integrity during the nanoprecipitation procedure
(Figure 3). The excipient mβCD has been used before to
improve enzyme activity in organic solvents [24]. The
excipient was co-dissolved with the protein previous to
the solvent precipitation step with acetonitrile. Because
mβCD is soluble in acetonitrile, the excipient was removed
by repeated centrifugation/washing cycles. Our results
show that the excipient further improved bioactivity to
96% and decreased the particle diameter to 90 nm.
The impact of the nanoprecipitation procedure on Cyt c
tertiary structure was investigated by circular dichroism
(CD) measurements after dissolving the NPs in buffer
(Figure 3B). The near-UV CD spectra show that the nano-
precipitation procedure did not cause irreversible changes
in the protein conformation. The two minima at 286 and
293 nm, characteristic of native Cyt c [25], were present in
all NP formulations. However, these two minima were
somewhat reduced when mβCD was used at the very high
1:20 mass ratio during nanoprecipitation. Since these two
minima correspond to Trp-59 [15] and cyclodextrins have
Figure 2 Effect of the protein concentration during Cyt c nanoprecipitation. The particle diameter (─●─) and precipitation yield (─◊─)
were determined for different protein concentration.
Figure 3 The effect of methyl-β-cyclodextrin (mβCD) during the protein precipitation. (A) Effect of mβCD on the particle diameter (─●─)
and caspase-3 activation (─□─) after Cyt c nanoprecipitation. (B) Near-UV CD spectrum of Cyt c nanoprecipitated in absence or presence of
mβCD. (C) SEM image of Cyt c NPs made without mβCD (upper picture), and at a 1:8 Cyt c-to-mβCD mass ratio (lower image).
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surfaces [26] it is possible that Cyt c was somewhat desta-
bilized by the additive under these conditions. Such
destabilization has been reported for some proteins under
aqueous and non-aqueous conditions [24,27].
Scanning electron microscopy (SEM) was performed
to investigate the shape of the NPs (Figure 3C). The
SEM images of lyophilized Cyt c NP formulations show
that the powder particles obtained had a spherical shape
and confirm that the particle size was in the nanometer
range.
Above findings demonstrate that the nanoprecipitation
method is useful in obtaining nano-scale Cyt c without
introducing irreversible functional loss. We also demon-
strated that the protein was still able to interact with
Apaf-1 to induce apoptosis upon rehydration.
Surface modification of Cyt c NPs
To make the nanoparticles useful for delivery purposes
we proceeded to modify their surface using a two-step
procedure (Figure 4). First, the NPs’ surface was modi-
fied with the linker SPDP to allow for their coating with
PLGA-SH. The level of SPDP modification was deter-
mined by measuring the release of pyridine-2-thione at
343 nm after addition of dithiothreitol (DTT) to the
reaction products. An increasing amount of linker was
attached to the NPs at increasing reagent concentration
during the reaction (Figure 5A). Since some of the target
amino groups of Cyt c overlap with the Cyt c-Apaf 1
interaction site, increased levels of SPDP linked to Cyt c
NPs reduced the ability of Cyt c to interact with Apaf-1 by
about 20% (Figure 5A). However, since a large amount of
Cyt c should be delivered to each single target cell in the
end (a complete NP with roughly over 100,000 molecules),
this was acceptable for our application. Circular dichroism
(CD) spectra showed that no major changes in Cyt cFigure 4 Scheme of the surface modification of Cyt c NPs with PLGA-tertiary structure occurred upon modification with SPDP
(Figure 5B). We selected the 5 fold-SPDP modification
level for PLGA attachment to have sufficient polymer
attachment points.
Next, the PLGA polymer was attached to the linker-
modified (activated) NPs in order to prevent them to
dissolve in aqueous media (e.g., upon reconstitution in
buffer). The level of modification accomplished with
PLGA-SH was determined by spectrophotometric ana-
lysis of the 2-pyridyldithio group released upon synthesis
(Figure 4) at 343 nm. The level of modification of the
NPs with PLGA was determined to be 2.06 ± 0.04 moles
per mol of Cyt c under the conditions employed (see
Methods Section for details). This construct is referred
to from here on as PLGA-S-S-Cyt c NPs.
Finally, we verified whether the constructs obtained
would behave in the manner we anticipated – stable in
aqueous medium under oxidizing conditions and dis-
solving after reduction-induced polymer shedding under
intracellular conditions. PLGA-S-S-Cyt c NPs were
placed in release buffer using glutathione concentrations
of 0, 1 μM, and 10 mM and incubated at 37°C simulating
extra- and intracellular conditions [28]. At pre-determined
times the supernatant was removed and the concentration
of dissolved Cyt c determined by measuring the heme
absorbance at 530 nm. The supernatant was replaced to
maintain sink conditions. The concentration of the released
protein was used to construct cumulative release profiles
(Figure 6).
The PLGA coated Cyt c NPs released ca. 10% of Cyt c
during the experiment, most of it during the first few
hours as a “burst release”. The amount of burst com-
pares well with most conventional PLGA-based sus-
tained release devices. Release of >80% of Cyt c was
accomplished under reducing conditions demonstrating
that the system design idea proved correct.SH by using a linker.
Figure 5 Characterization of the modification of Cyt c NP surface with the SPDP linker. (A) SPDP modification level accomplished using
increasing reagent concentrations during synthesis (closed symbols) and effect of the modification on in vitro caspase-3 activation in a cell-free
system (open symbols). (B) Near-UV CD spectra of dissolved Cyt c NPs after modification with SPDP.
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To investigate whether the synthesized NPs would display
the desired effect on cancer cells, HeLa cells were incu-
bated with PLGA-S-S-Cyt c NPs at 25, 50, and 100 μg/ml
Cyt c concentration for 6 h. Cyt c NPs coated with PLGA
induced a significant reduction in cell viability after 6 h
of incubation, in particular at the 100 μg/ml Cyt c con-
centration (Figure 7). Several control experiments were
performed. PLGA was conjugated to the SPDP linker and
added to HeLa cells at the same concentration as in the
corresponding experiments with the highest PLGA-S-S-
Cyt c NPs concentration. No significant cytotoxicity wasobserved after 6 h (Figure 7) and even 24 h of incubation
(data not shown) with PLGA-SPDP. To further confirm
that the cell death after treatment with PLGA-S-S-Cyt c
NPs was due to Cyt c, we constructed the same PLGA
coated NPs delivery using the non-apoptotic protein α-
lactalbumin (LA). The LA-based NPs had no effect on cell
viability excluding cytotoxic effects of the delivery system
per se (Figure 7).
Similar to us, Zhao and coworkers designed a smart
nanoparticulate DDS for an apoptotic protein (i.e.,
caspase-3). The protein was released mediated by intra-
cellular reducing conditions. The study showed evidence
Figure 6 Sustained release of Cyt c from PLGA-coated NPs after exposure to various conditions.
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6 h for our DDS.
The DDS designed by us herein also proved much
more efficient in killing HeLa cells than our previous
smart DDS based on silica NPs [15]. Making the drug
Cyt c itself the nanoparticulate delivery system eliminated
the main problem encountered with the other system,
namely, increasing silica toxicity when trying to deliver
sufficient Cyt c to the target cells. Similarly, NPs using
other materials [29] could present similar issues as our
silica-based delivery system.Figure 7 Viability of HeLa cells treated with PLGA-S-S-Cyt c NPs after
PLGA-S-S-LA NPs) and had no effect on HeLa cell viability. Asterisk (***) indAnother potential advantage of the newly designed
DDS is its negative charge. Although positively charged
NPs have shown good cell internalization properties
[18,30,31], they potentially bind to vascular endothelial
cells reducing their tumor accumulation by means of the
EPR effect (i.e., the vascular endothelial luminal surface
is known to be negatively charged) [2]. In contrast,
PLGA has a negative charge at physiological and alka-
line pH and it has been demonstrated that it can be
internalized by the cell and is able to escape from the
endosomes [32]. Therefore, our protein-based NPs could6 h of incubation. Two controls were included (PLGA-SPDP,
icates statistical significance (p < 0.001).
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apoptotic proteins.
Investigation of apoptosis induction in HeLa cells by the
intracellular release of Cyt c
To confirm that the Cyt c-induced cell death observed in
the cell viability experiments was indeed due to apoptosis,
we assessed the occurrence of nuclear segmentation and
chromatin condensation. After HeLa cells were incubated
with PLGA-S-S-Cyt c NPs or the PLGA-S-S-LA NPs
control for 6 h, the cells were stained with PI and DAPI.
Co-localization of DAPI and PI occurred when cells
were incubated with Cyt c-based NPs (Figure 8), which
points toward nuclear fragmentation and chromatin
condensation in the cells indicative of ongoing apop-
tosis. In contrast, cells without treatment or treated
with the PLGA-S-S-LA control showed no indication
for dye co-localization and thus apoptosis. These results
are in agreement with confocal results by Santra et al
[7] who demonstrated that the delivery of Cyt c to the
cytoplasm of the cancer cells results in the induction of
apoptosis of such cells [7].
Conclusions
Therapeutic proteins have enormous potential in the
treatment and prevention of human diseases but are of
limited use because they frequently display low physico-
chemical stability. Specifically, when injected proteins
usually quickly degrade and have short blood half-lives.
Thus, the development of DDS able to protect theFigure 8 Study of DAPI and propidium iodine (PI) colocalization, for t
observed in HeLa cells incubated with the PLGA-S-S-Cyt c NPs. No cellular
PLGA-S-SLA NPs.protein payload from degradation and in addition enab-
ling targeted and controlled delivery is of considerable
interest. Herein, we presented a new method for the
delivery of Cyt c, an apoptotic protein, to model cancer
cells. The main advantage of the system is that the DDS
core consisted of Cyt c NPs and thus the drug itself thus
overcoming payload limitations of drug-loaded systems.
In order to stabilize the protein NPs we coated them
with hydrophobic PLGA using a redox-sensitive linker.
Only little Cyt c was released under oxidizing conditions,
but 80% was released within hours under intracellular
conditions. We furthermore demonstrated that PLGA-S-
S-Cyt c NPs were able to induce apoptosis in a human
cancer cell line while PLGA-S-S-LA NPs as control did
not. Redox-responsive polymer-coated protein-based NPs
are a simple and effective method for intracellular delivery
of Cyt c for induction of apoptosis. We foresee that this
system could potentially be used for the delivery of other
proteins. However, we like to point out that our system
was not tested in a non-cancerous cell line at this point in
time because it does not include targeting ligands. Thus, it
would probably show comparable toxicity in cancer and
non-cancer cell lines since the EPR effect afforded by the
nanoparticle formulation would not be relevant in vitro
studies. It is also important to acknowledge that particle
size is by far not the sole determinant of tumor specificity
in in vivo studies. For example, immune cells can con-
sume the drug delivery system and some tumors maybe
very dense in the core disabling EPR-mediated targeting.
To address such questions, experiments ongoing in ourhe detection of apoptotic cells. Selective induction of apoptosis
apoptosis observed in untreated HeLa cells or when incubated with
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models. Tumor selectivity and internalization kinetics
and mechanism of PLGA-S-S-Cyt c NPs are being scru-
tinized as well as the decoration of the system with
tumor specific ligands. Combining passive targeting with
additional ligand-mediating targeting should not only
amplify the specificity of the NPs but also facilitate their
efficient cellular uptake.
Experimental procedures
Cytochrome c from equine heart, reduced glutathione
ethyl ester, and a protease inhibitor cocktail were from
Sigma-Aldrich (St. Louis, MO). Acetonitrile (HPLC grade)
was from Fisher (Waltham, MA). Succinimidyl-3-(2-pyri-
dyldithio) propionate (SPDP) was from Proteochem
(Denver, CO). Poly (lactide-co-glycolide)-SH with a thiol
end cap (PLGA-SH, 30,000 Da, copolymer ratio 1:1) was
from Akina, Inc (West Lafayette, IN). 4’, 6-Diamidino-
2-phenylindole (DAPI) and propidium iodide (PI) were
purchased from Invitrogen (Grand Island, NY). All the
reagents were used without further purification. All
other chemicals were from various commercial suppliers
and were at least of analytical grade. HeLa cells were
purchased from the American Type Culture Collection
(Manassas, VA) and grown according to the vendor’s
instruction.
Protein nanoprecipitation
Protein nanoparticles were obtained using a similar method
as described previously by us [14]. Briefly, Cyt c was
solvent-precipitated from nanopure water in presence of
the excipient methyl-β-cyclodextrin by adding acetonitrile
at a 1:4 volume ratio. Different protein concentrations
(5, 10, 20, 40 mg/ml) as well as different mass ratios of
protein-to-excipient (1:4, 1:8, 1:20 and 1:40, w/w) were
studied. The protein suspension obtained was centrifuged
at 6,000 rpm for 15 min, the supernatant discarded, and
the pellet vacuum dried for 30 min.
Determination of the nanoprecipitation yield
Protein concentration and amount of protein aggregates
in Cyt c NPs were determined as described by us in detail
[33]. In brief, the Cyt c NPs were suspended in 2 ml of
potassium phosphate (PBS) buffer for 2 h to dissolve the
buffer-soluble fraction. The samples were then subjected
to centrifugation at 6,000 rpm for 15 min and the super-
natant used to determine the protein concentration.
Next, 1 ml of 6 M urea was added to the pellet to dissolve
the buffer-insoluble protein fraction. The protein concen-
tration was determined by quantitative ultraviolet (UV)
spectrophotometric analysis at 280 nm and also from
the heme absorbance at 408 nm. The precipitation yield
was calculated from the actual and theoretical quantity of
protein recovered after nanoprecipitation and rehydration(%w/w). Cyt c as obtained from the supplier in PBS or
6 M urea was used to construct a calibration curve. The
experiments were performed in triplicate, the results
averaged, and the standard deviations calculated.
Synthesis of SPDP-Cyt c NPs
Following the Cyt c nanoprecipitation, the SPDP linker
was added directly to the resulting suspension (i.e., in 80%
acetonitrile) to accomplish the NPs surface modification
with the linker. Different Cyt c-to-SPDP molar ratios
(1:2.5, 1:5, 1:10) were tested. After letting the mixture
react for 30 min, the suspension was used to determinate
the level of modification with SPDP. To stop the reaction
and to remove unreacted SPDP and N-hydroxysuccini-
mide by-products, repeated centrifugation (6,000 rpm,
15 min)/washing cycles were performed. The pyridyl-
dithiol-activated Cyt c (SPDP-Cyt c) NPs pellet was saved
for further reaction and analysis. The supernatant was
used to determine the concentration of unreacted SPDP
by measuring the release of pyridine-2-thione at 343 nm
after addition of 10 μL of 15 mg/ml DTT (the absorbance
of the supernatant before reaction with DTT was used
as blank). The amount of covalent modification of the
nanoparticles with the linker was determined from the
difference between the initial SPDP concentration and
the unreacted SPDP. The experiments were performed in
triplicate, the results averaged, and the standard deviations
calculated.
Synthesis of PLGA-Cyt c NPs
HS-PLGA (50 mg) dissolved into 5 ml of Acetonitrile was
added to SPDP-Cyt c NPs (5 mg) and reacted at room
temperature for 18 h. After reaction, unreacted HS-PLGA
and pyridine 2-thione by-products were removed by cen-
trifugation at 6,000 rpm for 10 min. The supernatant was
used to determine the level of modification by measuring
the concentration of pyridine-2-thione at 343 nm.
In vitro release of Cyt c
The release of Cyt c from PLGA-S-S-Cyt c NPs was
measured similarly as described by us [28]. Briefly,
0.25 mg of PLGA-S-S-Cyt c NPs powder were sus-
pended by sonication in 1 ml of 50 mM PBS with 1 mM
EDTA at pH 7.4 and glutathione (GHS) concentrations
of 0, 0.001, and 10 mM. Incubation was performed for
various times at 37°C, and the NPs were pelleted by
centrifugation at 14,000 rpm for 10 min. The supernatant
was removed and used to determine the concentration of
released Cyt c. The pellet was resuspended in GHS-PBS
buffer. The amount of protein released was used to
construct cumulative release profiles. The experiments
were performed in triplicate, the results averaged, and
the standard deviations calculated.
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Particle sizes of the different formulations of Cyt c NPs
were determined by Dynamic light scattering using a
DynaPro Titan. The samples were dispersed in DMF and
subjected to ultrasonication at 240 W for 30 sec prior to
the measurements.
Scanning electron microscope (SEM)
SEM of the different formulations of Cyt c NPs was per-
formed using a JEOL 5800LV scanning electron microscope
at 20 kV. The samples were coated with gold for 10 sec to a
thinkness of 10 nm using a Denton Vacuum DV-502A.
Circular dichroism (CD) spectroscopy
CD spectra were recorded using a JASCO J-1500 High
Performance CD spectrometer at room temperature. The
protein (Cyt c, Cyt c NPs, or SPDP-Cyt c NPs) was
dissolved in nanopure water. CD spectra were acquired
from 260 to 350 nm (tertiary structure) at a concentration
of 1 mg/ml using a 10 mm quartz cuvette. Each spectrum
was obtained by averaging two scans. Spectra of nanopure
water blanks were measured prior to the samples and
subtracted from the sample spectra.
Cell-free caspase-3 assay
The cell lysate was obtained as described by us [15].
Briefly, the cell-free reaction was initiated by adding Cyt
c or the different Cyt c NP formulations (e.g. 100 μg/mL
of Cyt c NPs or SPDP-Cyt c NPs) to freshly purified
cytosol (3 mg/ml) in a total reaction volume of 100 μL. The
reaction was incubated at 37°C for 150 min. Afterwards the
caspase-3 assay was performed following the manufac-
turer’s protocol (CaspACE™ assay; Promega, Madison, WI).
The plate was incubated overnight at room temperature
and the absorbance at 405 nm was measured in each well
using a Thermo Scientific Multiskan FC. All measurements
were performed in triplicate.
Cell culture
HeLa cells were maintained in accordance with the
ATCC protocol. Briefly, the cells were cultured in mini-
mum essential medium (MEM) containing 1% L-gluta-
mine, 10% fetal bovine serum (FBS), and 1% penicillin in
a humidified incubator with 5% CO2 and 95% air at 37°
C. All experiments were conducted before cells reached
25 passages. For the cell viability and confocal micros-
copy experiments, HeLa cells were seeded in 96-well
plates or chambered cover-slides (4 wells), respectively,
for 24 h in MEM containing 1% L-glutamine, 10% FBS,
and 1% penicillin. Subsequently, cell growth was arrested
by decreasing the FBS concentration in the medium to
1% for 18 h. Then, cells were exposed and incubated
with the different bioconjugates for 6 h.Cell viability assay
Mitochondrial function was measured using the CellTi-
ter 96 aqueous non-radioactive cell proliferation assay
from Promega Corporation. HeLa cells (5,000 cells/well)
were seeded in 96-well plates as described above. Cells
were incubated with serial dilutions of PLGA-S-S-Cyt c
NPs (25, 50 and 100 μg/mL of Cyt c) for 6 h. Controls, such
as, PLGA-SPDP (80 μg/mL) and NPs of a non-apoptotic
protein (i.e. α-lactalbumin at 100 μg/mL) were also tested.
After incubation, 20 μL of 3-(4, 5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium, inner salt (MTS) and phenazine methosulfate (PMS)
was added to each well (333 μg/mL MTS and 25 μM
PMS). After 1 h, the absorbance at 492 nm was measured
using a microplate reader. HeLa cells treated with 2 μM
staurosporin for 6 h were used as positive control and
cells without treatment were used as negative control. The
relative cell viability (%) was calculated by:
Relative cell viability %ð Þ ¼ Abs test sample
Abscontrol
 100
T-test analysis was used for comparison of two inde-
pendent groups for cell viability. Difference between
control (untreated cells) and experimental groups (i.e.,
PLGA-SPDP, PLGA-S-S-LA, NPs PLGA-S-S-Cyt c NPs)
was considered statistically significant at p < 0.05.
Investigation of apoptosis induction in HeLa cells by the
intracellular release of Cyt c
HeLa cells (25,000 cells) were seeded in chambered cover-
glass (4-wells) as previously described by us [15]. The cells
were incubated with PLGA-S-S-Cyt c NPs at a 25 μg/mL Cyt
c concentration at 37°C for 6 h. For detection of apoptosis-
dependent nuclear fragmentation, the cells were washed with
PBS (1X) and incubated initially with DAPI (300 nM) and
thereafter with PI (75 μM) for 5 min each. HeLa cells were
then fixed using 3.7% formaldehyde. The coverslips were
examined under a Zeiss laser-scanning microscope 510 using
a 67× objective. Co-localization of DAPI and PI upon inter-
nalization into HeLa cells was determined, which is represen-
tative of highly condensed and fragmented chromatin in
apoptotic cells [7,34,35]. DAPI was excited at 405 nm and its
emission was detected at 420-480 nm. PI was excited at
561 nm and was detected above 600-674 nm.
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